Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

GETINGE MEDICAL TECHNOLOGY RDI (RSFF)

Signature(s)

Amount
€ 53,501,899.64
Countries
Sector(s)
Sweden : € 53,501,899.64
Industry : € 53,501,899.64
Signature date(s)
19/06/2008 : € 53,501,899.64
Link to source
Data sheet
GETINGE MEDICAL TECHNOLOGY RDI (RSFF)
Other links
Summary sheet
Getinge Medical Technology RDI

Summary sheet

Release date
7 September 2007
Status
Reference
Signed | 19/06/2008
20060542
Project name
Promoter - financial intermediary
Getinge Medical Technology RDI

Getinge AB

Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
Loan up to SEK 500 million. (EUR 54 million)
Approximately SEK 1 billion. (EUR 109 million)
Location
Sector(s)
Description
Objectives

The project concerns the part-financing of Getinge Group’s annual R&D expenditures in the 2007-2010 period.

The project aims at maintaining and further developing Getinge’s leading position in the fields of medical care and technology.

Environmental aspects
Procurement

The execution of the RDI programme will have no material environmental impact. All national and EU environmental legislation will be respected.

The promoter is a private company and therefore not bound by EC Directives on procurement.

Comments

Article 267, point (c)

Link to source
Summary sheet
Getinge Medical Technology RDI
Other links
Data sheet
GETINGE MEDICAL TECHNOLOGY RDI (RSFF)

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications